Figure 1 Statins, ezetimibe, and PCSK9 inhibitors all increase the expression of LDL receptors and reduce LDL-cholesterol levels (by percentages shown)

Slides:

Advertisements

Similar presentations

New Insights in the Understanding of Cholesterol Metabolism: The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Regulation of Low-Density.

Advertisements

Kirk Mykytyn, Ph.D. Department of Pharmacology

Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial Z. Awan, N.G. Seidah, J.G.

Cholesterol Metabolism and the Concept of Dual Inhibition David E. Cohen, MD, PhD.

J Am Coll Cardiol. 2015;65(24): doi: /j.jacc Figure Legend:

Overview Lipoprotein metabolism Digestive lipid metabolism

Kendrick Sparks, PGY3 September 17, 2015

Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Discovery of a New Role of Human Resistin in Hepatocyte.

Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Test in Context: High-Sensitivity C-Reactive Protein.

Evolocumab Drugbank ID : DB09303.

By: Dr Israa Omar MBBS, MRCP, MSc pharmacology

Robert Roberts, MD, FRCPC, MACC Canadian Journal of Cardiology

The Latest Lipid Guidelines:

Nat. Rev. Cardiol. doi: /nrcardio

Recommendation of NLA Expert Panel on Treatment With PCSK9 Inhibitors

Effect of Low Cholesterol on Steroid Hormones and Vitamin E Levels

Dual regulation of the LDL receptor—Some clarity and new questions

Figure 7 Mendelian randomization of overlapping exposures

Antilipidaemic agents

An Endocrinology Clinic in Dyslipidemia

Nat. Rev. Cardiol. doi: /nrcardio

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.

Cholesteryl Ester Transfer Protein Inhibitors

Figure 2 Hepatic action of functional foods and supplements

Figure 3 Metabolism pathway of antiplatelet agents

Figure 2 Binding properties of P2Y12-receptor inhibitors

Advances in Dyslipidemia: What Have We Learned From ACC 2017

What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs? Raul D. Santos Atherosclerosis.

Figure 1 Newly discovered mechanistic pathways

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 Sterol regulatory element-binding

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Antiplatelet and anticoagulant pathways

Figure 1 Inducers of the NLRP3 inflammasome related

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Evaluating LDL-C Recommendations

Nat. Rev. Endocrinol. doi: /nrendo

Figure 1 Overview of lipoprotein metabolism and effects of novel lipid-modulating approaches Figure 1 | Overview of lipoprotein metabolism and effects.

Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency Don P. Wilson, MD, FNLA, Mark Friedman,

My Approach to the Patient With Familial Hypercholesterolemia

Nat. Rev. Cardiol. doi: /nrcardio

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia Joep C. Defesche, PhD,

New LDL-C Lipid Targets

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

Updates in Cardiovascular Medicine

Figure 5 Examples of biomarker-guided trials

New Therapeutic Approaches to the Treatment of Dyslipidemia

Figure 3 Challenges for big data applications in cardiovascular care

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.

Volume 130, Issue 6, Pages (May 2006)

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Copyright © 2016 Elsevier Inc. All rights reserved.

Nat. Rev. Cardiol. doi: /nrcardio

Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease Guenther Silbernagel, MD, Iris Baumgartner, MD, Christoph Wanner, MD,

Figure 1 The major pathways of lipid metabolism

Lipid Updates From Spring 2019

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Tremblay AJ. Et al. J Lipid Res 2009 Mar 22 [Epub ahead of print]

PCSK9 Inhibitors and Statin Intolerance

Nat. Rev. Cardiol. doi: /nrcardio

Insights in the Understanding of Cholesterol Metabolism:

in diabetic patients with mixed dyslipidemia

Fig. 2. Effects of CB_36 and its analogs in HepG2 cells

Presentation transcript:

Figure 1 Statins, ezetimibe, and PCSK9 inhibitors all increase the expression of LDL receptors and reduce LDL-cholesterol levels (by percentages shown) Figure 1 | Statins, ezetimibe, and PCSK9 inhibitors all increase the expression of LDL receptors and reduce LDL-cholesterol levels (by percentages shown). Statins inhibit cholesterol synthesis in the liver, ezetimibe blocks cholesterol absorption in the intestine, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors block the PCSK9-mediated degradation of LDL receptors. Grundy, S. M. (2016) Advances in treatment of dyslipidaemia Nat. Rev. Cardiol. doi:10.1038/nrcardio.2015.208